Global Spinal Muscular Atrophy Medicine Market Research Report 2020

Global Spinal Muscular Atrophy Medicine Market Research Report 2020

Table of Contents
1 Spinal Muscular Atrophy Medicine Market Overview
1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine
1.2 Spinal Muscular Atrophy Medicine Segment by Type
1.2.1 Global Spinal Muscular Atrophy Medicine Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 LMI-070
1.2.3 ND-602
1.2.4 NT-1654
1.2.5 Nusinersen
1.2.6 NXD-30001
1.2.7 Others
1.3 Spinal Muscular Atrophy Medicine Segment by Application
1.3.1 Spinal Muscular Atrophy Medicine Sales Comparison by Application: 2020 VS 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts
1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2015-2026
1.4.2 Global Spinal Muscular Atrophy Medicine Sales 2015-2026
1.4.3 Spinal Muscular Atrophy Medicine Market Size by Region: 2020 Versus 2026
2 Global Spinal Muscular Atrophy Medicine Market Competition by Manufacturers
2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2015-2020)
2.2 Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2015-2020)
2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Sites, Area Served, Product Type
2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Spinal Muscular Atrophy Medicine Players (Opinion Leaders)
3 Spinal Muscular Atrophy Medicine Retrospective Market Scenario by Region
3.1 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country
3.3.2 North America Spinal Muscular Atrophy Medicine Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country
3.4.2 Europe Spinal Muscular Atrophy Medicine Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region
3.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
3.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.6.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country
3.6.2 Latin America Spinal Muscular Atrophy Medicine Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country
3.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country
3.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Type
4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2015-2020)
4.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2015-2020)
4.3 Global Spinal Muscular Atrophy Medicine Price Market Share by Type (2015-2020)
4.4 Global Spinal Muscular Atrophy Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Application
5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2015-2020)
5.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2015-2020)
5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2015-2020)
6 Company Profiles and Key Figures in Spinal Muscular Atrophy Medicine Business
6.1 Astellas Pharma Inc.
6.1.1 Corporation Information
6.1.2 Astellas Pharma Inc. Description, Business Overview and Total Revenue
6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Astellas Pharma Inc. Products Offered
6.1.5 Astellas Pharma Inc. Recent Development
6.2 AveXis, Inc.
6.2.1 AveXis, Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.2.2 AveXis, Inc. Description, Business Overview and Total Revenue
6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.2.4 AveXis, Inc. Products Offered
6.2.5 AveXis, Inc. Recent Development
6.3 Bioblast Pharma Ltd.
6.3.1 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.3.2 Bioblast Pharma Ltd. Description, Business Overview and Total Revenue
6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Bioblast Pharma Ltd. Products Offered
6.3.5 Bioblast Pharma Ltd. Recent Development
6.4 Cytokinetics, Inc. 24
6.4.1 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.4.2 Cytokinetics, Inc. 24 Description, Business Overview and Total Revenue
6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Cytokinetics, Inc. 24 Products Offered
6.4.5 Cytokinetics, Inc. 24 Recent Development
6.5 F. Hoffmann-La Roche Ltd.
6.5.1 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.5.2 F. Hoffmann-La Roche Ltd. Description, Business Overview and Total Revenue
6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.5.4 F. Hoffmann-La Roche Ltd. Products Offered
6.5.5 F. Hoffmann-La Roche Ltd. Recent Development
6.6 Genethon
6.6.1 Genethon Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.6.2 Genethon Description, Business Overview and Total Revenue
6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Genethon Products Offered
6.6.5 Genethon Recent Development
6.7 Genzyme Corporation
6.6.1 Genzyme Corporation Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.6.2 Genzyme Corporation Description, Business Overview and Total Revenue
6.6.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Genzyme Corporation Products Offered
6.7.5 Genzyme Corporation Recent Development
6.8 GMP-Orphan SAS
6.8.1 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.8.2 GMP-Orphan SAS Description, Business Overview and Total Revenue
6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.8.4 GMP-Orphan SAS Products Offered
6.8.5 GMP-Orphan SAS Recent Development
6.9 Ionis Pharmaceuticals, Inc.
6.9.1 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.9.2 Ionis Pharmaceuticals, Inc. Description, Business Overview and Total Revenue
6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Ionis Pharmaceuticals, Inc. Products Offered
6.9.5 Ionis Pharmaceuticals, Inc. Recent Development
6.10 Longevity Biotech, Inc
6.10.1 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.10.2 Longevity Biotech, Inc Description, Business Overview and Total Revenue
6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.10.4 Longevity Biotech, Inc Products Offered
6.10.5 Longevity Biotech, Inc Recent Development
6.11 Neurodyn Inc.
6.11.1 Neurodyn Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.11.4 Neurodyn Inc. Products Offered
6.11.5 Neurodyn Inc. Recent Development
6.12 Neurotune AG
6.12.1 Neurotune AG Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.12.4 Neurotune AG Products Offered
6.12.5 Neurotune AG Recent Development
6.13 Novartis AG
6.13.1 Novartis AG Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.13.2 Novartis AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.13.4 Novartis AG Products Offered
6.13.5 Novartis AG Recent Development
6.14 Sarepta Therapeutics, Inc.
6.14.1 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.14.4 Sarepta Therapeutics, Inc. Products Offered
6.14.5 Sarepta Therapeutics, Inc. Recent Development
6.15 Voyager Therapeutics, Inc.
6.15.1 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.15.4 Voyager Therapeutics, Inc. Products Offered
6.15.5 Voyager Therapeutics, Inc. Recent Development
6.16 Vybion, Inc.
6.16.1 Vybion, Inc. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.16.4 Vybion, Inc. Products Offered
6.16.5 Vybion, Inc. Recent Development
6.17 WAVE Life Sciences Ltd.
6.17.1 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Production Sites and Area Served
6.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue
6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)
6.17.4 WAVE Life Sciences Ltd. Products Offered
6.17.5 WAVE Life Sciences Ltd. Recent Development
7 Spinal Muscular Atrophy Medicine Manufacturing Cost Analysis
7.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine
7.4 Spinal Muscular Atrophy Medicine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Spinal Muscular Atrophy Medicine Distributors List
8.3 Spinal Muscular Atrophy Medicine Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Spinal Muscular Atrophy Medicine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Type (2021-2026)
10.2 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Application (2021-2026)
10.3 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Region (2021-2026)
10.4 North America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)
10.5 Europe Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)
10.6 Asia Pacific Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)
10.7 Latin America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)
10.8 Middle East and Africa Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Comparison by Application: 2020 VS 2026
Table 3. Global Spinal Muscular Atrophy Medicine Market Size by Type (K Pcs) (US$ Million) (2020 VS 2026)
Table 4. Global Key Spinal Muscular Atrophy Medicine Manufacturers Covered in This Study
Table 5. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Manufacturers (2015-2020)
Table 6. Global Spinal Muscular Atrophy Medicine Sales Share by Manufacturers (2015-2020)
Table 7. Global Spinal Muscular Atrophy Medicine Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Spinal Muscular Atrophy Medicine Average Price (USD/Pcs) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Spinal Muscular Atrophy Medicine Sales Sites and Area Served
Table 11. Manufacturers Spinal Muscular Atrophy Medicine Product Types
Table 12. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2019)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Spinal Muscular Atrophy Medicine Players
Table 16. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Region (2015-2020)
Table 17. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2015-2020)
Table 18. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) by Region (2015-2020)
Table 19. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2015-2020)
Table 20. North America Spinal Muscular Atrophy Medicine Sales by Country (2015-2020) (K Pcs)
Table 21. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2015-2020)
Table 22. North America Spinal Muscular Atrophy Medicine Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2015-2020)
Table 24. Europe Spinal Muscular Atrophy Medicine Sales by Country (2015-2020) (K Pcs)
Table 25. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country (2015-2020)
Table 26. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2015-2020) (K Pcs)
Table 29. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2015-2020)
Table 32. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2015-2020) (K Pcs)
Table 33. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country (2015-2020)
Table 34. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2015-2020) (K Pcs)
Table 37. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country (2015-2020)
Table 40. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Type (2015-2020)
Table 41. Global Spinal Muscular Atrophy Medicine Sales Share by Type (2015-2020)
Table 42. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) by Type (2015-2020)
Table 43. Global Spinal Muscular Atrophy Medicine Revenue Share by Type (2015-2020)
Table 44. Global Spinal Muscular Atrophy Medicine Price (USD/Pcs) by Type (2015-2020)
Table 45. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) by Application (2015-2020)
Table 46. Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2015-2020)
Table 47. Global Spinal Muscular Atrophy Medicine Sales Growth Rate by Application (2015-2020)
Table 48. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 49. Astellas Pharma Inc. Description and Business Overview
Table 50. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 51. Astellas Pharma Inc. Main Product
Table 52. Astellas Pharma Inc. Recent Development
Table 53. AveXis, Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 54. AveXis, Inc. Corporation Information
Table 55. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 56. AveXis, Inc. Main Product
Table 57. AveXis, Inc. Recent Development
Table 58. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Corporation Information
Table 59. Bioblast Pharma Ltd. Corporation Information
Table 60. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 61. Bioblast Pharma Ltd. Main Product
Table 62. Bioblast Pharma Ltd. Recent Development
Table 63. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Corporation Information
Table 64. Cytokinetics, Inc. 24 Corporation Information
Table 65. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 66. Cytokinetics, Inc. 24 Main Product
Table 67. Cytokinetics, Inc. 24 Recent Development
Table 68. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Corporation Information
Table 69. F. Hoffmann-La Roche Ltd. Corporation Information
Table 70. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 71. F. Hoffmann-La Roche Ltd. Main Product
Table 72. F. Hoffmann-La Roche Ltd. Recent Development
Table 73. Genethon Spinal Muscular Atrophy Medicine Corporation Information
Table 74. Genethon Corporation Information
Table 75. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 76. Genethon Main Product
Table 77. Genethon Recent Development
Table 78. Genzyme Corporation Spinal Muscular Atrophy Medicine Corporation Information
Table 79. Genzyme Corporation Corporation Information
Table 80. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Genzyme Corporation Main Product
Table 82. Genzyme Corporation Recent Development
Table 83. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Corporation Information
Table 84. GMP-Orphan SAS Corporation Information
Table 85. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. GMP-Orphan SAS Main Product
Table 87. GMP-Orphan SAS Recent Development
Table 88. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 89. Ionis Pharmaceuticals, Inc. Corporation Information
Table 90. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Ionis Pharmaceuticals, Inc. Main Product
Table 92. Ionis Pharmaceuticals, Inc. Recent Development
Table 93. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Corporation Information
Table 94. Longevity Biotech, Inc Corporation Information
Table 95. Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Longevity Biotech, Inc Main Product
Table 97. Longevity Biotech, Inc Recent Development
Table 98. Neurodyn Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 99. Neurodyn Inc. Corporation Information
Table 100. Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Neurodyn Inc. Main Product
Table 102. Neurodyn Inc. Recent Development
Table 103. Neurotune AG Spinal Muscular Atrophy Medicine Corporation Information
Table 104. Neurotune AG Corporation Information
Table 105. Neurotune AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Neurotune AG Main Product
Table 107. Neurotune AG Recent Development
Table 108. Novartis AG Spinal Muscular Atrophy Medicine Corporation Information
Table 109. Novartis AG Corporation Information
Table 110. Novartis AG Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Novartis AG Main Product
Table 112. Novartis AG Recent Development
Table 113. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 114. Sarepta Therapeutics, Inc. Corporation Information
Table 115. Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Sarepta Therapeutics, Inc. Main Product
Table 117. Sarepta Therapeutics, Inc. Recent Development
Table 118. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 119. Voyager Therapeutics, Inc. Corporation Information
Table 120. Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 121. Voyager Therapeutics, Inc. Main Product
Table 122. Voyager Therapeutics, Inc. Recent Development
Table 123. Vybion, Inc. Spinal Muscular Atrophy Medicine Corporation Information
Table 124. Vybion, Inc. Corporation Information
Table 125. Vybion, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 126. Vybion, Inc. Main Product
Table 127. Vybion, Inc. Recent Development
Table 128. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Corporation Information
Table 129. WAVE Life Sciences Ltd. Corporation Information
Table 130. WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (Million US$), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 131. WAVE Life Sciences Ltd. Main Product
Table 132. WAVE Life Sciences Ltd. Recent Development
Table 133. Sales Base and Market Concentration Rate of Raw Material
Table 134. Key Suppliers of Raw Materials
Table 135. Spinal Muscular Atrophy Medicine Distributors List
Table 136. Spinal Muscular Atrophy Medicine Customers List
Table 137. Market Key Trends
Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 139. Key Challenges
Table 140. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Forecast by Type (2021-2026)
Table 141. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Type (2021-2026)
Table 142. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) Forecast by Type (2021-2026)
Table 143. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 144. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Forecast by Application (2021-2026)
Table 145. Global Spinal Muscular Atrophy Medicine Revenue (Million US$) Forecast by Application (2021-2026)
Table 146. Global Spinal Muscular Atrophy Medicine Sales (K Pcs) Forecast by Region (2021-2026)
Table 147. Global Spinal Muscular Atrophy Medicine Sales Market Share Forecast by Region (2021-2026)
Table 148. Global Spinal Muscular Atrophy Medicine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 149. Global Spinal Muscular Atrophy Medicine Revenue Market Share Forecast by Region (2021-2026)
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Spinal Muscular Atrophy Medicine
Figure 2. Global Spinal Muscular Atrophy Medicine Sales Market Share by Type: 2020 VS 2026
Figure 3. LMI-070 Product Picture
Figure 4. ND-602 Product Picture
Figure 5. NT-1654 Product Picture
Figure 6. Nusinersen Product Picture
Figure 7. NXD-30001 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Spinal Muscular Atrophy Medicine Consumption Market Share by Application: 2020 VS 2026
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Spinal Muscular Atrophy Medicine Market Size 2015-2026 (US$ Million)
Figure 14. Global Spinal Muscular Atrophy Medicine Sales Capacity (K Pcs) (2015-2026)
Figure 15. Global Spinal Muscular Atrophy Medicine Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Spinal Muscular Atrophy Medicine Sales Share by Manufacturers in 2020
Figure 17. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers in 2019
Figure 18. The Global 5 and 10 Largest Players: Market Share by Spinal Muscular Atrophy Medicine Revenue in 2019
Figure 19. Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 20. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2015-2020)
Figure 21. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2019
Figure 22. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2015-2020)
Figure 23. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region in 2019
Figure 24. North America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2019
Figure 25. North America Spinal Muscular Atrophy Medicine Revenue Market Share by Country in 2019
Figure 26. U.S. Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 27. U.S. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 28. Canada Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 29. Canada Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 30. Europe Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2019
Figure 31. Europe Spinal Muscular Atrophy Medicine Revenue Market Share by Country in 2019
Figure 32. Germany Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 33. Germany Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. France Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 35. France Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. U.K. Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.K. Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Italy Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Italy Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Russia Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. Russia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Asia Pacific Spinal Muscular Atrophy Medicine Sales Market Share by Region in 2019
Figure 43. Asia Pacific Spinal Muscular Atrophy Medicine Revenue Market Share by Region in 2019
Figure 44. China Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. China Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. Japan Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Japan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. South Korea Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. South Korea Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. India Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. India Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Australia Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Australia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Taiwan Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Taiwan Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Indonesia Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Indonesia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Thailand Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. Thailand Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Malaysia Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Malaysia Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Philippines Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Philippines Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Vietnam Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Vietnam Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Latin America Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2019
Figure 67. Latin America Spinal Muscular Atrophy Medicine Revenue Market Share by Country in 2019
Figure 68. Mexico Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Mexico Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Brazil Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Brazil Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Argentina Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Argentina Spinal Muscular Atrophy Medicine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Middle East and Africa Spinal Muscular Atrophy Medicine Sales Market Share by Country in 2019
Figure 75. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue Market Share by Country in 2019
Figure 76. Turkey Spinal Muscular Atrophy Medicine Sales Growth Rate (2015-2020) (K Pcs

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs